AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21642845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based multidisciplinary rehabilitation program plus oral medication
Number of subjects: 197
Study 21642845 — intervention group
Group type: COMPARATOR
Intervention: Oral medication alone
Number of subjects: 197
Study 18423869 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants plus zinc supplementation
Number of subjects: 876
Study 18423869 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 876
Study 18423869 — intervention group
Group type: COMPARATOR
Intervention: Antioxidants supplementation
Number of subjects: 876
Study 18423869 — intervention group
Group type: COMPARATOR
Intervention: No zinc supplementation
Number of subjects: 876
Study 18423869 — intervention group
Group type: COMPARATOR
Intervention: No antioxidants supplementation
Number of subjects: 876
Study 16490803 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg administered with a high-fat/high-calorie meal
Number of subjects: 0
Study 16490803 — intervention group
Group type: COMPARATOR
Intervention: Telbivudine 600 mg administered without a high-fat/high-calorie meal (fasting)
Number of subjects: 0
Study 12427406 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 454
Study 12427406 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 454
Study 10353617 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine pretreatment (910 mg/m2)
Number of subjects: 19
Study 10353617 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (cisplatin, adriamycin, cyclophosphamide)
Number of subjects: 19
Study 8668059 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg esmolol IV
Number of subjects: 75
Study 8668059 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg esmolol IV
Number of subjects: 75
Study 8668059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 1971318 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) alone
Number of subjects: 50
Study 1971318 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (amoxicillin and metronidazole with CBS)
Number of subjects: 50
Study 7395772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine (0.5 g for 8 weeks, then 1.0 g for 6 weeks)
Number of subjects: 16
Study 7395772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6387632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 55
Study 6387632 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 55
Study 6387632 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nutritional supplementation and relaxation training
Number of subjects: 55
Study 6387632 — intervention group
Group type: COMPARATOR
Intervention: Neither nutritional supplementation nor relaxation training (Control)
Number of subjects: 55
Study 30939091 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 1178
Study 30939091 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT) in low TILs group
Number of subjects: 1178
Study 30939091 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT) in high TILs group
Number of subjects: 1178
Study 30939091 — intervention group
Group type: EXPERIMENTAL
Intervention: High TILs
Number of subjects: 1178
Study 30939091 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 50 years
Number of subjects: 1178
Study 30939091 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 vs Grade 1
Number of subjects: 1178
Study 29580569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 58
Study 29580569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 29580569 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 58
Study 28361826 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg once daily for six months)
Number of subjects: 54
Study 28361826 — intervention group
Group type: COMPARATOR
Intervention: Control (no carvedilol)
Number of subjects: 54
Study 25300260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle advice (n = 1,108)
Number of subjects: 2212
Study 25300260 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 1,104)
Number of subjects: 2212
Study 22244567 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (4 periods of 5 minutes of lower limb ischemia intercalated with 5 minutes of reperfusion)
Number of subjects: 22
Study 22244567 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 21203731 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid 25 percent by brushing for 1 or 3 minutes
Number of subjects: 270
Study 21203731 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 270
Study 17933193 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week periodized resistance training (experimental group, n = 10)
Number of subjects: 16
Study 17933193 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 16
Study 17933193 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 10)
Number of subjects: 16
Study 16097906 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided Internet coping group
Number of subjects: 62
Study 16097906 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 62
Study 11807353 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of short gastric vessels
Number of subjects: 99
Study 11807353 — intervention group
Group type: COMPARATOR
Intervention: No division of short gastric vessels
Number of subjects: 99
Study 9873217 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard water (Ca2+ 255 mg/l)
Number of subjects: 18
Study 9873217 — intervention group
Group type: COMPARATOR
Intervention: Soft water (Ca2+ 22 mg/l, Fiuggi water)
Number of subjects: 18
Study 9873217 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 18
Study 7668962 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Number of subjects: 2
Study 7668962 — intervention group
Group type: COMPARATOR
Intervention: Hands-assisted standing-up
Number of subjects: 2
Study 2140325 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa (100 mg)
Number of subjects: 6
Study 2140325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7031872 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 daily doses of 220 mg oral zinc sulfate
Number of subjects: 0
Study 7031872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30345895 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of agricultural stressors
Number of subjects: 70
Study 30345895 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived effects of agricultural stressors
Number of subjects: 70
Study 30345895 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping mechanisms for agricultural stressors
Number of subjects: 70
Study 29895590 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral renal denervation using therapeutic levels of ultrasound energy (n=12)
Number of subjects: 23
Study 29895590 — intervention group
Group type: COMPARATOR
Intervention: Sham application of diagnostic ultrasound (n=11)
Number of subjects: 23
Study 26801470 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐management of Osteoarthritis and Low back pain through Activity and Skills (SOLAS) intervention
Number of subjects: 0
Study 26801470 — intervention group
Group type: COMPARATOR
Intervention: Usual individual physiotherapy
Number of subjects: 0
Study 24946626 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion applied to Zusanli (ST 36) and Sanyinjiao (SP 6), 2-3 times a day for 4 weeks, 3 sessions total.
Number of subjects: 109
Study 24946626 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment continued for 3 months follow-up.
Number of subjects: 109
Study 24946626 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment before and after treatment comparison.
Number of subjects: 109
Study 24946626 — intervention group
Group type: COMPARATOR
Intervention: Control group received regular hemodialysis and conventional medication without moxibustion.
Number of subjects: 109
Study 23058854 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of ketorolac tromethamine in 1 L of normal saline
Number of subjects: 135
Study 23058854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 20643988 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing for contextual red flags
Number of subjects: 111
Study 20643988 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing for biomedical red flags
Number of subjects: 111
Study 20643988 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-free treatment plans in uncomplicated encounters
Number of subjects: 111
Study 20643988 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-free treatment plans in biomedically complicated encounters
Number of subjects: 111
Study 20643988 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-free treatment plans in contextually complicated encounters
Number of subjects: 111
Study 20643988 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-free treatment plans in combined biomedically and contextually complicated encounters
Number of subjects: 111
Study 17684777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic plate (ABC, Aesculap, Germany)
Number of subjects: 132
Study 17684777 — intervention group
Group type: COMPARATOR
Intervention: Rigid plate (CSLP, Synthes, Switzerland)
Number of subjects: 132
Study 16236834 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-triphosphate (ATP)
Number of subjects: 20
Study 16236834 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 20
Study 15571441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 g/kg alcohol
Number of subjects: 10
Study 15571441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 10
Study 15571441 — intervention group
Group type: COMPARATOR
Intervention: 0.0 g/kg (placebo)
Number of subjects: 10
Study 10726009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprosulate 0.5 mg/kg body weight
Number of subjects: 18
Study 10726009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprosulate 1.0 mg/kg body weight
Number of subjects: 18
Study 10726009 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (Calciparin 7,500 IU)
Number of subjects: 18
Study 7734259 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 40 mg kg‐1 i.v. pretreatment
Number of subjects: 0
Study 7734259 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium without magnesium pretreatment
Number of subjects: 0
Study 2203304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime and tobramycin given concurrently to normal volunteers
Number of subjects: 0
Study 2203304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime and tobramycin given concurrently to anuric patients
Number of subjects: 0
Study 2203304 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime and tobramycin given separately
Number of subjects: 0
Study 7038839 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 (PGE2), 0.33 mg three times daily
Number of subjects: 0
Study 7038839 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(R)15 Me PGE2, 40 micrograms three times daily
Number of subjects: 0
Study 7038839 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin, 50 mg three times daily
Number of subjects: 0
Study 28440549 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. cable TV consumption
Number of subjects: 330
Study 26946614 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-movement therapy (AM)
Number of subjects: 60
Study 26946614 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture (CA)
Number of subjects: 60
Study 26946614 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture-movement therapy (SAM)
Number of subjects: 60
Study 26946614 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 60
Study 25203651 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte solution (CE)
Number of subjects: 19
Study 25203651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon tea (LT)
Number of subjects: 19
Study 25203651 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (DW)
Number of subjects: 19
Study 22765882 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider education and access to a CKD registry
Number of subjects: 418
Study 22765882 — intervention group
Group type: COMPARATOR
Intervention: Control clinic (education only)
Number of subjects: 418
Study 22765882 — intervention group
Group type: EXPERIMENTAL
Intervention: Control and intervention clinics
Number of subjects: 418
Study 20658390 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic noise conditions (even, lumped) with 20%, 40% heavy vehicles
Number of subjects: 102
Study 20658390 — intervention group
Group type: EXPERIMENTAL
Intervention: High noise sensitivity
Number of subjects: 102
Study 17980202 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical simulator laboratory on laparoscopic tubal ligation
Number of subjects: 20
Study 17980202 — intervention group
Group type: COMPARATOR
Intervention: Apprenticeship teaching alone
Number of subjects: 20
Study 16327260 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 0
Study 16327260 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel alone
Number of subjects: 0
Study 12135710 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair (OHR) with routine mesh repair
Number of subjects: 4688
Study 12135710 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair (OHR) with mesh
Number of subjects: 4688
Study 12135710 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (LHR)
Number of subjects: 4688
Study 9689830 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine coronary angiogram (CAG)
Number of subjects: 50
Study 9689830 — intervention group
Group type: COMPARATOR
Intervention: Risk factors for CAD (smoking, hypertension, hypercholesterolemia, diabetes)
Number of subjects: 50
Study 7989943 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for patients with measurable disease
Number of subjects: 426
Study 7989943 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for patients with assessable disease
Number of subjects: 426
Study 7989943 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for all patients
Number of subjects: 426
Study 7989943 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival of responders only
Number of subjects: 426
Study 7989943 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessable disease
Number of subjects: 426
Study 7989943 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 426
Study 2692375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin therapy
Number of subjects: 64
Study 2692375 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 29575386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 189
Study 29575386 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 189
Study 26699231 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Teen Leaders Avoiding Screen‐time (ATLAS) intervention
Number of subjects: 361
Study 25156082 — intervention group
Group type: EXPERIMENTAL
Intervention: Luliconazole cream 1%
Number of subjects: 0
Study 25156082 — intervention group
Group type: COMPARATOR
Intervention: Controlled drugs or vehicle
Number of subjects: 0
Study 25156082 — intervention group
Group type: COMPARATOR
Intervention: 1% terbinafine
Number of subjects: 0
Study 25156082 — intervention group
Group type: COMPARATOR
Intervention: 1% bifonazole
Number of subjects: 0
Study 25156082 — intervention group
Group type: COMPARATOR
Intervention: 0.1% or 0.5% luliconazole
Number of subjects: 0
Study 22490808 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up infliximab therapy (5 mg/kg body weight, induction regimen of 3 doses at week 0, 2, and 6, maintenance every 8 weeks starting at week 14)
Number of subjects: 41
Study 22490808 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down infliximab therapy (5 mg/kg body weight, induction regimen of 3 doses at week 0, 2, and 6, maintenance every 8 weeks starting at week 14)
Number of subjects: 41
Study 22490808 — intervention group
Group type: COMPARATOR
Intervention: Step-up infliximab therapy
Number of subjects: 41
Study 22490808 — intervention group
Group type: COMPARATOR
Intervention: Top-down infliximab therapy
Number of subjects: 41
Study 20381933 — intervention group
Group type: COMPARATOR
Intervention: Nut consumption <1 time/week
Number of subjects: 21078
Study 20381933 — intervention group
Group type: COMPARATOR
Intervention: Nut consumption 1 time/week
Number of subjects: 21078
Study 20381933 — intervention group
Group type: COMPARATOR
Intervention: Nut consumption 2-4 times/week
Number of subjects: 21078
Study 20381933 — intervention group
Group type: COMPARATOR
Intervention: Nut consumption 5-6 times/week
Number of subjects: 21078
Study 20381933 — intervention group
Group type: COMPARATOR
Intervention: Nut consumption ≥7 times/week
Number of subjects: 21078
Study 18441453 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 45
Study 18441453 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 45
Study 15842582 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 g/day)
Number of subjects: 110
Study 15842582 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (800 IU/day)
Number of subjects: 110
Study 15842582 — intervention group
Group type: COMPARATOR
Intervention: Prescriptive weight-reducing diet
Number of subjects: 110
Study 14562993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional calcium intake (Ca)
Number of subjects: 937
Study 14562993 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 937
Study 10817000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1 MAC
Number of subjects: 80
Study 10817000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.5 MAC
Number of subjects: 80
Study 10817000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2 MAC
Number of subjects: 80
Study 10817000 — intervention group
Group type: COMPARATOR
Intervention: TIVA with fentanyl and propofol
Number of subjects: 80
Study 9133197 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 15 mu g/kg
Number of subjects: 119
Study 9133197 — intervention group
Group type: COMPARATOR
Intervention: saline control
Number of subjects: 119
Study 9133197 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 30 mu g/kg
Number of subjects: 119
Study 9133197 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 1.0 mg/kg
Number of subjects: 119
Study 9133197 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 15 mu g/kg and alfentanil 30 mu g/kg
Number of subjects: 119
Study 8213541 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg IS-5-MN
Number of subjects: 214
Study 8213541 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg IS-5-MN
Number of subjects: 214
Study 8213541 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg IS-5-MN
Number of subjects: 214
Study 8213541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 2890369 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg etretin daily
Number of subjects: 80
Study 2890369 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg etretin daily
Number of subjects: 80
Study 2890369 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg etretin daily
Number of subjects: 80
Study 2890369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29777950 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus a 1-day ACT workshop (n=44)
Number of subjects: 88
Study 29777950 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n=44)
Number of subjects: 88
Study 27297519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% (w/w)
Number of subjects: 0
Study 27297519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% (w/w)
Number of subjects: 0
Study 27297519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 10% (w/w)
Number of subjects: 0
Study 27297519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (all doses)
Number of subjects: 0
Study 24729537 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 99
Study 24729537 — intervention group
Group type: COMPARATOR
Intervention: Control (health education videos)
Number of subjects: 99
Study 24280467 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetotherapy (25Hz, 450 pulse/s, 5‐80G, 20 min/day for 10 days)
Number of subjects: 50
Study 22378291 — intervention group
Group type: COMPARATOR
Intervention: High saturated fatty acids diet
Number of subjects: 466
Study 22378291 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acids diet
Number of subjects: 466
Study 22378291 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 466
Study 19250161 — intervention group
Group type: EXPERIMENTAL
Intervention: LHA formulation (twice a day)
Number of subjects: 80
Study 19250161 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide (5%, once a day)
Number of subjects: 80
Study 16707816 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram and low nickel diet (LND) for 4 weeks
Number of subjects: 21
Study 16707816 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose tablet) with normal diet for 4 weeks
Number of subjects: 21
Study 15106392 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic cat
Number of subjects: 0